Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate HUTCHMED (China) Ltd (ADR) before investing.

In this article, we go over a few key elements for understanding HUTCHMED (China) Ltd (ADR)’s stock price such as:

• HUTCHMED (China) Ltd (ADR)’s current stock price and volume
• Why HUTCHMED (China) Ltd (ADR)’s stock price changed recently
• Upgrades and downgrades for HCM from analysts
• HCM’s stock price momentum as measured by its relative strength

About HUTCHMED (China) Ltd (ADR) (HCM)

Before we jump into HUTCHMED (China) Ltd (ADR)’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D;) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Want to learn more about HUTCHMED (China) Ltd (ADR)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about HUTCHMED (China) Ltd (ADR).

HUTCHMED (China) Ltd (ADR)’s Stock Price as of Market Close

As of July 08, 2024, 4:00 PM, CST, HUTCHMED (China) Ltd (ADR)’s stock price was $16.70.

HUTCHMED (China) Ltd (ADR) is down 9.53% from its previous closing price of $18.46.

During the last market session, HUTCHMED (China) Ltd (ADR)’s stock traded between $18.16 and $18.56. Currently, there are 170.48 million shares of HUTCHMED (China) Ltd (ADR) stock available for purchase.

HUTCHMED (China) Ltd (ADR)’s price-earnings (P/E) ratio is currently at 32.1, which is high compared to the Pharmaceuticals industry median of 23.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

HUTCHMED (China) Ltd (ADR) Stock Price History

HUTCHMED (China) Ltd (ADR)’s (HCM) price is currently down 2.45% so far this month.

During the month of July, HUTCHMED (China) Ltd (ADR)’s stock price has reached a high of $18.56 and a low of $16.64.

Over the last year, HUTCHMED (China) Ltd (ADR) has hit prices as high as $21.92 and as low as $11.91. Year to date, HUTCHMED (China) Ltd (ADR)’s stock is up 12.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused HUTCHMED (China) Ltd (ADR) Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 05, 2024, there were analysts who downgraded HUTCHMED (China) Ltd (ADR)’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate HUTCHMED (China) Ltd (ADR)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on HUTCHMED (China) Ltd (ADR)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

HUTCHMED (China) Ltd (ADR)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about HUTCHMED (China) Ltd (ADR) (HCM) by visiting AAII Stock Evaluator.

Relative Price Strength of HUTCHMED (China) Ltd (ADR)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 05, 2024, HUTCHMED (China) Ltd (ADR) has a weighted four-quarter relative price strength of 5.58%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how HUTCHMED (China) Ltd (ADR) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

HUTCHMED (China) Ltd (ADR) Stock Price: Bottom Line

As of July 8, 2024, HUTCHMED (China) Ltd (ADR)’s stock price is $16.70, which is down 9.53% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like HUTCHMED (China) Ltd (ADR) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.